Skip to main content
Premium Trial:

Request an Annual Quote

Incyte to Market Drug Profiling System from MDS Pharma and Iconix

NEW YORK, Dec. 12 — MDS Pharma Services and Iconix Pharmaceuticals announced Wednesday an agreement to develop a new system to evaluate drug efficacy and toxicity. The system, called DrugMatrix, will combine chemical, genomic, and pharmacological information to allow for rapid profiling of drug candidates. Incyte, which entered an agreement with and made an equity investment in Iconix in May 2001, will commercialize the new platform.

The two firms will collaborate on developing the system. Montreal-based MDS Pharma Services will make an equity investment in Iconix of Mountain View, Calif., and commit additional money and resources to the development partnership. Other financial details of the partnership were not disclosed.

MDS Pharma Services will profile thousands of benchmark drug molecules to create a standardized source of comprehensive pharmacological information on both successful and unsuccessful drug candidates. Iconix will provide genomic expression array profiling and chemical indexing of the molecules.

Privately held Iconix is known for its work in the field of “chemogenomics,” the effort to connect genomic data with information about pharmacology, toxicology and drug molecule structure.

Iconix integrated Incyte’s LifeExpress Lead database into its current chemogenomics system. Incyte has exclusive marketing rights to the new platform.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.